Table 2.
Summary of adverse events
| Pasireotide long-acting release | ||||
|---|---|---|---|---|
| Adverse events n (%) | 20 (mg) n = 12 |
40 (mg) n = 14 |
60 (mg) n = 16 |
Total N = 42 |
| Any adverse event | 10 (83.3) | 11 (78.6) | 13 (81.3) | 34 (81.0) |
| Diarrhea | 4 (33.3) | 4 (28.6) | 4 (25.0) | 12 (28.6) |
| Fatigue | 3 (25.0) | 3 (21.4) | 3 (18.8) | 9 (21.4) |
| Abdominal pain | 3 (25.0) | 4 (28.6) | 1 (6.3) | 8 (19.0) |
| Nausea | 2 (16.7) | 3 (21.4) | 2 (12.5) | 7 (16.7) |
| Diabetes mellitus | 1 (8.3) | 3 (21.4) | 2 (12.5) | 6 (14.3) |
| Dyspnea | 2 (16.7) | 3 (21.4) | 1 (6.3) | 6 (14.3) |
| Flushing | 3 (25.0) | 1 (7.1) | 2 (12.5) | 6 (14.3) |
| Headache | 1 (8.3) | 2 (14.3) | 3 (18.8) | 6 (14.3) |
| Anorexia | 1 (8.3) | 3 (21.4) | 1 (6.3) | 5 (11.9) |
| Asthenia | 2 (16.7) | 2 (14.3) | 1 (6.3) | 5 (11.9) |
| Treatment-related adverse event | 6 (50) | 10 (71.4) | 8 (50) | 24 (57.1) |
| Diabetes mellitus | 1 (8.3) | 3 (21.4) | 1 (6.3) | 5 (11.9) |
| Hyperglycemia | 0 | 2 (14.3) | 2 (12.5) | 4 (9.5) |
| Serious adverse event | 1 (8.3) | 2 (14.3) | 2 (12.5) | 5 (11.9) |
| Discontinued because of adverse event | 1 (8.3) | 3 (21.4) | 1 (6.3) | 5 (11.9) |
Individual AEs occurring in >10 % of patients across all treatment arms are presented